For a long time, cancer treatment options were riddled with chemo-therapies, which did not differentiate between good and bad cells and therefore ended up killing them. Clay Siegall saw this and embarked on a journey to develop targeted therapies to treat major unmet needs. In the late 1990s, Mr. Siegall co-founded Seattle Genetics on the pillars of scientific innovation, rigorous research and drug development practices. The firm is developing a diverse portfolio of clinical and pre-clinical product candidates targeting a variety of cancer and autoimmune indications.
Clay Siegall, a scientist by training, has decades of experience in cancer research. He has a PhD. in Genetics from George Washington University and a Bachelor of Science in Zoology from the University of Maryland from which he received the Alumnus of the year for Math, Computer, and Natural Science in 2013. He also received the Pacific Northwestern Ernst & Young Entrepreneur of the year in the healthcare category in 2012.
Clay Siegall’s Impressive Experience in Cancer Research
Mr. Siegall holds 15 patents in a bid to advance research into cancer treatments and has been published more than 70 times. He has a passion for sharing his tremendous experiences and knowledge in new research methods and discoveries. Before the birth of Seattle Genetics, Clay worked at Squibb Pharmaceutical Research Institute, National Cancer Institute and the National Institute of Health. Dr. Clay Siegall serves on the Board of Governors of Fred Hutchinson Cancer Research Business and Board of Directors of Mirna Therapeutics. Mirna is hoping to benefit from his extensive knowledge.
Dr. Siegall has shown excellent efforts in ensuring the success of Seattle Genetics for the good of cancer patients everywhere. Over five years the stock price of the company has tripled. He has raised more than $675 Million through public donation and private funding deals. Under Dr. Clay Siegall’s stewardship, the company has secured a position of pride in the field of Antibody Drug Conjugates (ADCs). In 2011, the FDA approved ADCETRIS which is now available to help cancer patients in more than 65 countries. A perfect world for Dr. Clay Siegall is one in that cancer patients no longer have to suffer.